Salmon Calcitonin

Salmon calcitonin is a synthetic 32-amino acid peptide identical in sequence to the calcitonin produced by the ultimobranchial glands of salmon. Despite differing from human calcitonin in 16 of 32 amino acid positions, salmon calcitonin binds to human calcitonin receptors with significantly higher affinity and has approximately 40-50 times greater biological potency than human calcitonin. This enhanced potency is attributed to differences in the peptide's amphipathic alpha-helical structure that improve receptor interaction and resistance to enzymatic degradation.

Salmon calcitonin has been used therapeutically since the early 1970s and was one of the earliest peptide drugs to achieve widespread clinical adoption. It works by binding to calcitonin receptors on osteoclasts, causing rapid morphological changes (loss of ruffled border and contraction of the osteoclast cell body) that result in cessation of bone resorption within minutes of administration. This rapid onset of action makes it particularly valuable in the acute management of hypercalcemia.

The drug is available in both injectable (subcutaneous/intramuscular) and intranasal spray formulations. The nasal spray formulation became the predominant route of administration for osteoporosis treatment due to better patient acceptance, despite having only approximately 25-50% of the bioavailability of the injectable form. The injectable form is preferred for acute indications such as hypercalcemia and Paget's disease where higher drug levels are needed.

Regulatory concerns have affected salmon calcitonin's clinical standing. In 2012, the European Medicines Agency recommended against long-term use of calcitonin-containing medicines based on a meta-analysis suggesting a small but statistically significant increase in cancer risk. The FDA subsequently also reviewed this data, and while nasal calcitonin remains available in the US, its use has become more restricted, particularly for chronic osteoporosis management.